Corporate
2026.05.29
USPTO Grants Dosing Regimen Patent for Lumosa’s LT3001
Corporate
2026.05.28
Lumosa Held Its Annual General Shareholders' Meeting Today
Corporate
2026.05.26
Lumosa Receives TFDA Approval for Phase 2 Exploratory Study of LT3001's Mechanism
Corporate
2026.04.01
Lumosa Announces Amendment to LT3001 Licensing Agreement with Shanghai Pharma
Corporate
2026.03.03
Dr. Devlin Shares LT3001 Clinical Results in VJNEurology Interview
Corporate
2026.02.20
LUMOSA's Novel Stroke Drug LT3001 Clears FDA Review
Opening the Door to a $10.6 Billion Market Opportunity